How to improve the risk-benefit ratio of cyclosporin therapy for psoriasis

CsA therapy for psoriasis is hampered by side-effects. Topical CsA therapy is not effective. Therefore improvement of the risk-benefit ratio must be achieved by improvement of dose-regimens, combination therapy of CsA with another therapy for psoriasis or combination therapy of CsA with a therapy that may influence the pathogenesis of the most serious side-effect(s) of CsA. It seems that only therapies that influence the pathogenesis of CsA-induced acute renal-impairment, like oral fish oil or perhaps thromboxane synthesis inhibitors, may be beneficial. However, further studies are warranted to validate these findings.